Meeting of the National Advisory Council for Healthcare Research and Quality, 32871-32872 [2018-15105]
Download as PDF
<![CDATA[
sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 83, No. 136 / Monday, July 16, 2018 / Notices
of the resolution period; and (ii) if
exercising such right would
economically benefit the counterparty
(‘‘counterparty-initiated termination’’).
• Time horizon: The duration of the
resolution period should be between 12
and 24 months. The resolution period
begins immediately after the parent
company bankruptcy filing and extends
through the completion of the preferred
resolution strategy.
A dealer firm’s analysis of its
derivatives strategy should, at a
minimum, take into account (i) the
starting profile of its derivatives
portfolios (e.g., nature, concentration,
maturity, clearability, and liquidity of
positions); (ii) the profile and function
of the derivatives entities during the
resolution period; (iii) the means,
challenges, and capacity for managing
and de-risking its derivatives portfolios
(e.g., method for timely segmenting,
packaging, and selling the derivatives
positions; challenges with novating less
liquid positions; re-hedging strategy);
(iv) the financial and operational
resources required to effect the
derivatives strategy; and (v) any
potential residual portfolio (further
discussed below). In addition, the firm’s
resolution plan should address the
following areas in the analysis of its
derivatives strategy:
Forecasts of resource needs. The
forecasts of capital and liquidity
resource needs required to adequately
support the firm’s derivatives strategy
should be incorporated into the firm’s
RCEN and RLEN estimates for its overall
preferred resolution strategy. These
include, for example, the costs and/or
liquidity flows resulting from (i) the
close-out of OTC derivatives, (ii) the
hedging of derivatives portfolios, (iii)
the quantified losses that could be incur
due to basis and other risks that would
result from hedging with only exchangetraded and centrally cleared instruments
in a severely adverse stress
environment, and (iv) the operational
costs.
Potential residual derivatives
portfolio. A dealer firm’s resolution plan
should include a method for estimating
the composition of any potential
residual derivatives portfolio
transactions remaining at the end of the
resolution period under its preferred
resolution strategy. The method may be
a combination of approaches (e.g.,
probabilistic and deterministic) but
should demonstrate the dealer firm’s
capabilities related to portfolio
segmentation (discussed above). The
dealer firm’s plan should also provide
detailed descriptions of the trade
characteristics used to identify the
potential residual portfolio and of the
VerDate Sep<11>2014
17:31 Jul 13, 2018
Jkt 244001
32871
resulting trades (or categories of
trades).58 A dealer firm should assess
the risk profile of the potential residual
portfolio (including its anticipated size,
composition, complexity,
counterparties) and the potential
counterparty and market impacts of
non-performance on the stability of U.S.
financial markets (e.g., on funding
markets and the underlying asset
markets and on clients and
counterparties).
Non-surviving entity analysis. To the
extent the preferred resolution strategy
assumes a material derivatives entity
enters its own resolution proceeding
after the entry of the parent company
into a bankruptcy proceeding (a ‘‘nonsurviving material derivatives entity’’),
the dealer firm should provide a
detailed analysis of how the nonsurviving material derivatives entity’s
resolution can be accomplished within
a reasonable period of time and in a
manner that substantially mitigates the
risk of serious adverse effects on U.S.
financial stability and to the orderly
execution of the firm’s preferred
resolution strategy. In particular, the
firm should provide an analysis of the
potential impacts on funding markets
and the underlying asset markets, on
clients and counterparties (including
affiliates), and on the preferred
resolution strategy. If the non-surviving
material derivatives entity is located in,
or provides more than de minimis
services to clients or counterparties
located in, a non-U.S. jurisdiction, then
the analysis should also specifically
consider potential local market impacts.
resources and loss-absorbing capacity of
the firm.
The discussion of strategy in the
public section should broadly explain
how the firm has addressed any
deficiencies, shortcomings, and other
key vulnerabilities that the Agencies
have identified in prior Plan
submissions. For each material entity, it
should be clear how the strategy
provides for continuity, transfer, or
orderly wind-down of the entity and its
operations. There should also be a
description of the resulting organization
upon completion of the resolution
process.
The public section may note that the
resolution plan is not binding on a
bankruptcy court or other resolution
authority and that the proposed failure
scenario and associated assumptions are
hypothetical and do not necessarily
reflect an event or events to which the
firm is or may become subject.
VIII. PUBLIC SECTION
The purpose of the public section is
to inform the public’s understanding of
the firm’s resolution strategy and how it
works.
The public section should discuss the
steps that the firm is taking to improve
resolvability under the U.S. Bankruptcy
Code. The public section should
provide background information on
each material entity and should be
enhanced by including the firm’s
rationale for designating material
entities. The public section should also
discuss, at a high level, the firm’s intragroup financial and operational
interconnectedness (including the types
of guarantees or support obligations in
place that could impact the execution of
the firm’s strategy). There should also be
a high-level discussion of the liquidity
Agency for Healthcare Research and
Quality
58 If under the firm’s preferred resolution strategy,
any derivatives portfolios are transferred during the
resolution period by way of a line of business sale
(or similar transaction), then those portfolios should
nonetheless be included within the firm’s potential
residual portfolio analysis.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
By the Board of Governors of the Federal
Reserve System, June 28, 2018.
Ann E. Misback,
Secretary of the Board.
Dated at Washington, DC on June 28, 2018.
By order of the Board of Directors.
Federal Deposit Insurance Corporation.
Valerie Jean Best,
Assistant Executive Secretary.
[FR Doc. 2018–15066 Filed 7–13–18; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the National Advisory
Council for Healthcare Research and
Quality
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Notice of public meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, this
notice announces a meeting of the
National Advisory Council for
Healthcare Research and Quality.
DATES: The meeting will be held on
Wednesday, July 18, 2018, from 8:30
a.m. to 2:45 p.m.
ADDRESSES: The meeting will be held at
AHRQ, 5600 Fishers Lane, Rockville,
Maryland, 20857.
FOR FURTHER INFORMATION CONTACT:
Jaime Zimmerman, Designated
Management Official, at the Agency for
Healthcare Research and Quality, 5600
Fishers Lane, Mail Stop 06E37A,
Rockville, Maryland 20857, (301) 427–
SUMMARY:
E:\FR\FM\16JYN1.SGM
16JYN1
32872
Federal Register / Vol. 83, No. 136 / Monday, July 16, 2018 / Notices
1456. For press-related information,
please contact Alison Hunt at (301) 427–
1244 or Alison.Hunt@ahrq.hhs.gov.
If sign language interpretation or other
reasonable accommodation for a
disability is needed, please contact the
Food and Drug Administration (FDA)
Office of Equal Employment
Opportunity and Diversity Management
on (301) 827–4840, no later than
Tuesday, July 3, 2018. The agenda,
roster, and minutes will be available
from Ms. Bonnie Campbell, Committee
Management Officer, Agency for
Healthcare Research and Quality, 5600
Fishers Lane, Rockville, Maryland
20857. Ms. Campbell’s phone number is
(301) 427–1554.
SUPPLEMENTARY INFORMATION:
I. Purpose
The National Advisory Council for
Healthcare Research and Quality is
authorized by Section 941 of the Public
Health Service Act, 42 U.S.C. 299c. In
accordance with its statutory mandate,
the Council is to advise the Secretary of
the Department of Health and Human
Services and the Director of AHRQ on
matters related to AHRQ’s conduct of its
mission including providing guidance
on (A) priorities for health care research,
(B) the field of health care research
including training needs and
information dissemination on health
care quality and (C) the role of the
Agency in light of private sector activity
and opportunities for public private
partnerships. The Council is composed
of members of the public, appointed by
the Secretary, and Federal ex-officio
members specified in the authorizing
legislation.
sradovich on DSK3GMQ082PROD with NOTICES
II. Agenda
On Wednesday, July 18, 2018, the
Council meeting will convene at 8:30
a.m., with the call to order by the
Council Chair and approval of previous
Council summary notes. The meeting is
open to the public and will be available
via webcast at www.webconferences.
com/ahrq. The meeting will begin with
an update on AHRQ’s current research,
programs, and initiatives. The agenda
will also include updates on: AHRQ
Data, Analytics, and Insights; Making
Health Services Research Relevant to
the C-Suite; and AHRQ’s Opioids
efforts. The final agenda will be
available on the AHRQ website at
www.AHRQ.gov no later than Friday,
July 13, 2018.
Francis D. Chesley, Jr.,
Acting Deputy Director.
[FR Doc. 2018–15105 Filed 7–13–18; 8:45 am]
BILLING CODE 4160–90–P
VerDate Sep<11>2014
17:31 Jul 13, 2018
Jkt 244001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Agency for Healthcare Research
and Quality, HHS.
ACTION: Notice.
AGENCY:
This notice announces the
intention of the Agency for Healthcare
Research and Quality (AHRQ) to request
that the Office of Management and
Budget (OMB) approve the proposed
information collection project
‘‘Consumer Assessment of Healthcare
Providers and Systems (CAHPS)
Clinician and Group Survey Database.’’
DATES: Comments on this notice must be
received by September 14, 2018.
ADDRESSES: Written comments should
be submitted to: Doris Lefkowitz,
Reports Clearance Officer, AHRQ, by
email at doris.lefkowitz@AHRQ.hhs.gov.
Copies of the proposed collection plans,
data collection instruments, and specific
details on the estimated burden can be
obtained from the AHRQ Reports
Clearance Officer.
FOR FURTHER INFORMATION CONTACT:
Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427–1477, or by
emails at doris.lefkowitz@
AHRQ.hhs.gov.
SUMMARY:
SUPPLEMENTARY INFORMATION:
Proposed Project
Renewal of the Consumer Assessment of
Healthcare Providers and Systems
(CAHPS) Clinician and Group Survey
Database
In accordance with the Paperwork
Reduction Act, 44 U.S.C. 3501–3521,
AHRQ invites the public to comment on
this proposed information collection.
The CAHPS Database is a repository for
data from selected CAHPS surveys. The
primary purpose of the CAHPS Database
is to facilitate comparisons of CAHPS
survey results by survey users. This
voluntary compilation of survey results
from a large pool of data into a single
database enables survey users to
compare their own results to relevant
Database results. The CAHPS Database
also offers an important source of
primary data for research related to
consumer assessments of quality as
measured by CAHPS surveys.
The CAHPS Clinician & Group Survey
(CG–CAHPS) Database is the newest
component of the CAHPS Database. It
was developed in response to the
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
growing demand for Database results for
the various versions of the CG–CAHPS
Survey, including the 12-month and
Visit versions. In May 2011, the first set
of Database results for both the 12month and Visit versions was released
through the CAHPS Database Online
Reporting System.
AHRQ developed the database for
CAHPS CG Survey data following the
CAHPS Health Plan Database as a
model. The CAHPS Health Plan
Database was developed in 1998 in
response to requests from health plans,
purchasers, and CMS for survey data to
support public reporting of health plan
ratings, health plan accreditation and
quality improvement (OMB Control
Number 0935–0165, expiration 5/31/
2020). Demand for survey results from
the CG Survey has grown as well, and
therefore AHRQ developed a dedicated
Clinician and Group Database to
support benchmarking, quality
improvement, and research (OMB
Control Number 0935–0197, expiration
02/28/2019).
The CAHPS Database contains data
from AHRQ’s standardized CAHPS
Surveys which provide survey measures
of quality to health care purchasers,
consumers, regulators, and policy
makers. The Health Plan Database also
provides data for AHRQ’s annual
National Healthcare Quality and
Disparities Reports.
The goal of this project is to renew the
CAHPS CG Survey Database. This
database will continue to update the
CAHPS CG Database with the latest
results of the CAHPS CG Survey. These
results consist of 31 items that measure
5 areas or composites of patients’
experiences with physicians and staff in
outpatient medical practices. This
database can be used to do the
following:
(1) Improve care provided by
individual providers, sites of care,
medical groups, or provider networks.
(2) Offer several products and
services, including providing survey
results presented through an Online
Reporting System, summary chartbooks,
custom analyses, private reports in
Excel format, and data for research
purposes.
(3) Provides information to help
identify strengths and areas with
potential for improvement in patient
care. The five composite measures are:
Getting Timely Appointments, Care, and
Information
How Well Providers Communicate With
Patients
Helpful, Courteous, and Respectful
Office Staff
Providers’ Use of Information to
Coordinate Patient Care
E:\FR\FM\16JYN1.SGM
16JYN1
]]>Agencies
[Federal Register Volume 83, Number 136 (Monday, July 16, 2018)]
[Notices]
[Pages 32871-32872]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-15105]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Meeting of the National Advisory Council for Healthcare Research
and Quality
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Notice of public meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, this
notice announces a meeting of the National Advisory Council for
Healthcare Research and Quality.
DATES: The meeting will be held on Wednesday, July 18, 2018, from 8:30
a.m. to 2:45 p.m.
ADDRESSES: The meeting will be held at AHRQ, 5600 Fishers Lane,
Rockville, Maryland, 20857.
FOR FURTHER INFORMATION CONTACT: Jaime Zimmerman, Designated Management
Official, at the Agency for Healthcare Research and Quality, 5600
Fishers Lane, Mail Stop 06E37A, Rockville, Maryland 20857, (301) 427-
[[Page 32872]]
1456. For press-related information, please contact Alison Hunt at
(301) 427-1244 or [email protected].
If sign language interpretation or other reasonable accommodation
for a disability is needed, please contact the Food and Drug
Administration (FDA) Office of Equal Employment Opportunity and
Diversity Management on (301) 827-4840, no later than Tuesday, July 3,
2018. The agenda, roster, and minutes will be available from Ms. Bonnie
Campbell, Committee Management Officer, Agency for Healthcare Research
and Quality, 5600 Fishers Lane, Rockville, Maryland 20857. Ms.
Campbell's phone number is (301) 427-1554.
SUPPLEMENTARY INFORMATION:
I. Purpose
The National Advisory Council for Healthcare Research and Quality
is authorized by Section 941 of the Public Health Service Act, 42
U.S.C. 299c. In accordance with its statutory mandate, the Council is
to advise the Secretary of the Department of Health and Human Services
and the Director of AHRQ on matters related to AHRQ's conduct of its
mission including providing guidance on (A) priorities for health care
research, (B) the field of health care research including training
needs and information dissemination on health care quality and (C) the
role of the Agency in light of private sector activity and
opportunities for public private partnerships. The Council is composed
of members of the public, appointed by the Secretary, and Federal ex-
officio members specified in the authorizing legislation.
II. Agenda
On Wednesday, July 18, 2018, the Council meeting will convene at
8:30 a.m., with the call to order by the Council Chair and approval of
previous Council summary notes. The meeting is open to the public and
will be available via webcast at www.webconferences.com/ahrq com/ahrq. The
meeting will begin with an update on AHRQ's current research, programs,
and initiatives. The agenda will also include updates on: AHRQ Data,
Analytics, and Insights; Making Health Services Research Relevant to
the C-Suite; and AHRQ's Opioids efforts. The final agenda will be
available on the AHRQ website at www.AHRQ.gov no later than Friday,
July 13, 2018.
Francis D. Chesley, Jr.,
Acting Deputy Director.
[FR Doc. 2018-15105 Filed 7-13-18; 8:45 am]
BILLING CODE 4160-90-P
